<p>雅培（NYSE:ABT - 獲取免費報告）在週三更新了 2025 年第二季度的收益指引。該公司提供的每股收益指引為 1.230-1.270，而市場共識的每股收益預期為 1.250。該公司發佈了收入指引為-。雅培還將其 2025 財年的指引更新為每股收益 5.050-5.250。</p>
<p>獲取 <strong>雅培</strong> 的提醒：</p>
<h2>雅培股票表現</h2>
<ul>
<li>雅培將在 2025 年超越醫療保健股票</li>
</ul>
<p>雅培股票週三開盤價為 131.09 美元。雅培的 1 年最低價為 99.71 美元，1 年最高價為 141.23 美元。該公司的 50 日移動平均價為 130.62 美元，200 日移動平均價為 121.54 美元。公司的流動比率為 1.60，速動比率為 1.14，債務與股本比率為 0.32。公司的市值為 2273.5 億美元，市盈率為 17.32，市盈增長比率為 2.52，貝塔值為 0.80。</p>
<p>雅培（NYSE:ABT - 獲取免費報告）最近在 4 月 16 日發佈了季度收益數據。這家醫療產品製造商報告該季度每股收益為 1.09 美元，超出市場共識預期的 1.07 美元 0.02 美元。雅培的淨利潤率為 31.95%，股本回報率為 20.74%。該季度的收入為 103.6 億美元，而市場共識預期為 103.8 億美元。整體來看，股票研究分析師預測雅培在當前財年將發佈 5.14 的每股收益。</p>
<h2>雅培股息公告</h2>
<ul>
<li>這些是值得持有的頂級健康股票</li>
</ul>
<p>該公司最近宣佈了一項季度股息，將於 5 月 15 日支付。4 月 15 日的股東將獲得每股 0.59 美元的股息。除息日為 4 月 15 日。這代表着年化股息為 2.36 美元，股息收益率為 1.80%。雅培的股息支付比率（DPR）目前為 30.85%。</p>
<h2>分析師評級變動</h2>
<p>多家券商最近對 ABT 發佈了報告。巴克萊在 1 月 27 日的研究報告中重申了 “增持” 評級，並將雅培的目標價設定為 158.00 美元（上調自 149.00 美元）。加拿大皇家銀行在 1 月 21 日的報告中重申了 “跑贏大盤” 評級，並對雅培的目標價為 135.00 美元。StockNews.com 在 2 月 12 日的研究報告中將雅培的評級從 “強力買入” 下調至 “買入”。花旗在 3 月 4 日的報告中將雅培的目標價從 135.00 美元上調至 160.00 美元，並給予該股票 “買入” 評級。最後，Stifel Nicolaus 在 1 月 23 日的報告中將雅培的目標價從 130.00 美元上調至 135.00 美元，並給予該股票 “買入” 評級。四位投資分析師對該股票給予持有評級，十五位給予買入評級，一位給予強力買入評級。根據 MarketBeat，雅培目前的共識評級為 “適度買入”，平均目標價為 137.94 美元。</p>
<ul>
<li>MarketBeat 週迴顧 – 10/14 - 10/18</li>
</ul>
<p><strong>獲取我們對雅培的最新股票分析</strong></p>
<h2>雅培的內部買賣</h2>
<p>在其他新聞中，SVP Eric Shroff 在 3 月 3 日的交易中出售了 562 股該公司的股票。股票以 138.17 美元的平均價格出售，總交易額為 77,651.54 美元。交易後，這位高級副總裁現在直接持有 31,970 股公司的股票，價值約為 4,417,294.90 美元。這筆交易代表着他們持股比例減少了 1.73%。該出售在與 SEC 的法律文件中披露，可以通過此鏈接訪問。此外，EVP Andrea F. Wainer 在 3 月 3 日的交易中出售了 949 股雅培的股票。股票以 138.17 美元的平均價格出售，總價值為 131,123.33 美元。出售後，這位執行副總裁現在直接持有 74,381 股公司的股票，價值約為 10,277,222.77 美元。這筆交易代表着他們持股比例減少了 1.26%。該出售的披露可以在這裏找到。內部人士在上個季度出售了 116,449 股公司股票，價值 15,463,316 美元。內部人士持有公司股票的比例為 0.46%。</p>
<h2>機構資金流入和流出</h2>
<p>一家對沖基金最近增加了對雅培股票的持股。根據該公司在最近向證券交易委員會提交的文件，Brighton Jones LLC 在第四季度將其在雅培（NYSE:ABT - 免費報告）的持股增加了 10.1%。該基金在此期間購買了額外的 4,755 股後，持有 51,719 股這家醫療產品製造商的股票。Brighton Jones LLC 在雅培的持股在最近的報告期末價值為 5,850,000 美元。75.18% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於雅培</h2>
<p>（獲取免費報告）</p>
<p>雅培及其子公司在全球範圍內發現、開發、製造和銷售醫療保健產品。它分為四個部門：已建立的製藥產品、診斷產品、營養產品和醫療設備。該公司提供用於治療胰腺外分泌功能不足、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，超過雅培</li>
<li>什麼是熱門股票？熱門股票解析</li>
<li>黃金反彈持續：這三隻礦業股票可能受益</li>
<li>特殊目的收購公司（SPAC）你需要知道的事項</li>
<li>XPO 購買 5000 萬美元的自家股票：原因在這裏</li>
<li>如何知道一隻股票是否支付股息以及何時支付</li>
<li>特斯拉股票在即將公佈財報時瞄準突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在雅培嗎？</h2>
<p>在考慮雅培之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而雅培並不在名單上。</p>
<p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

雅培

<p>雅培（NYSE:ABT）更新了其 2025 年第二季度的收益指引，預計每股收益（EPS）在 1.230 到 1.270 之間，略低於市場共識預期的 1.250。該公司還修訂了 2025 財年的每股收益指引至 5.050-5.250。雅培的股票開盤價為 131.09 美元，市值為 2273.5 億美元，市盈率為 17.32。最近的分析師評級顯示共識為 “適度買入”，平均目標價為 137.94 美元。該公司宣佈每股季度分紅為 0.59 美元，將於 5 月 15 日支付</p>

<p>Abbott Laboratories (NYSE:ABT - Get Free Report) updated its second quarter 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.230-1.270 for the period, compared to the consensus earnings per share estimate of 1.250. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2025 guidance to 5.050-5.250 EPS.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）在週三更新了 2025 年第二季度的收益指引。該公司提供的每股收益指引為 1.230-1.270，而市場共識的每股收益預期為 1.250。該公司發佈了收入指引為-。雅培還將其 2025 財年的指引更新為每股收益 5.050-5.250。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>雅培</strong> 的提醒：</p>
</div><h2>Abbott Laboratories Stock Performance</h2>
<div class="lb-trans"><h2>雅培股票表現</h2>
</div><ul>
<li>Abbott Laboratories Will Outperform Healthcare Stocks in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培將在 2025 年超越醫療保健股票</li>
</ul>
</div><p>Shares of Abbott Laboratories stock opened at $131.09 on Wednesday. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $141.23. The company has a 50 day moving average of $130.62 and a 200-day moving average of $121.54. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The company has a market cap of $227.35 billion, a PE ratio of 17.32, a price-to-earnings-growth ratio of 2.52 and a beta of 0.80.</p>
<div class="lb-trans"><p>雅培股票週三開盤價為 131.09 美元。雅培的 1 年最低價為 99.71 美元，1 年最高價為 141.23 美元。該公司的 50 日移動平均價為 130.62 美元，200 日移動平均價為 121.54 美元。公司的流動比率為 1.60，速動比率為 1.14，債務與股本比率為 0.32。公司的市值為 2273.5 億美元，市盈率為 17.32，市盈增長比率為 2.52，貝塔值為 0.80。</p>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. As a group, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 獲取免費報告）最近在 4 月 16 日發佈了季度收益數據。這家醫療產品製造商報告該季度每股收益為 1.09 美元，超出市場共識預期的 1.07 美元 0.02 美元。雅培的淨利潤率為 31.95%，股本回報率為 20.74%。該季度的收入為 103.6 億美元，而市場共識預期為 103.8 億美元。整體來看，股票研究分析師預測雅培在當前財年將發佈 5.14 的每股收益。</p>
</div><h2>Abbott Laboratories Dividend Announcement</h2>
<div class="lb-trans"><h2>雅培股息公告</h2>
</div><ul>
<li>These Are The Top Health Stocks to Own for Buy-and-Hold Investing</li>
</ul>
<div class="lb-trans"><ul>
<li>這些是值得持有的頂級健康股票</li>
</ul>
</div><p>The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a dividend of $0.59 per share. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.80%. Abbott Laboratories's dividend payout ratio (DPR) is presently 30.85%.</p>
<div class="lb-trans"><p>該公司最近宣佈了一項季度股息，將於 5 月 15 日支付。4 月 15 日的股東將獲得每股 0.59 美元的股息。除息日為 4 月 15 日。這代表着年化股息為 2.36 美元，股息收益率為 1.80%。雅培的股息支付比率（DPR）目前為 30.85%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of brokerages have recently issued reports on ABT. Barclays restated an &#34;overweight&#34; rating and set a $158.00 price objective (up from $149.00) on shares of Abbott Laboratories in a research report on Monday, January 27th. Royal Bank of Canada restated an &#34;outperform&#34; rating and issued a $135.00 target price on shares of Abbott Laboratories in a report on Tuesday, January 21st. StockNews.com lowered Abbott Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Wednesday, February 12th. Citigroup increased their price target on Abbott Laboratories from $135.00 to $160.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, March 4th. Finally, Stifel Nicolaus upped their target price on shares of Abbott Laboratories from $130.00 to $135.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Abbott Laboratories presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $137.94.</p>
<div class="lb-trans"><p>多家券商最近對 ABT 發佈了報告。巴克萊在 1 月 27 日的研究報告中重申了 “增持” 評級，並將雅培的目標價設定為 158.00 美元（上調自 149.00 美元）。加拿大皇家銀行在 1 月 21 日的報告中重申了 “跑贏大盤” 評級，並對雅培的目標價為 135.00 美元。StockNews.com 在 2 月 12 日的研究報告中將雅培的評級從 “強力買入” 下調至 “買入”。花旗在 3 月 4 日的報告中將雅培的目標價從 135.00 美元上調至 160.00 美元，並給予該股票 “買入” 評級。最後，Stifel Nicolaus 在 1 月 23 日的報告中將雅培的目標價從 130.00 美元上調至 135.00 美元，並給予該股票 “買入” 評級。四位投資分析師對該股票給予持有評級，十五位給予買入評級，一位給予強力買入評級。根據 MarketBeat，雅培目前的共識評級為 “適度買入”，平均目標價為 137.94 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 10/14 - 10/18</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 10/14 - 10/18</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>獲取我們對雅培的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling at Abbott Laboratories</h2>
<div class="lb-trans"><h2>雅培的內部買賣</h2>
</div><p>In other news, SVP Eric Shroff sold 562 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the transaction, the senior vice president now directly owns 31,970 shares of the company's stock, valued at approximately $4,417,294.90. This trade represents a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrea F. Wainer sold 949 shares of Abbott Laboratories stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $131,123.33. Following the sale, the executive vice president now directly owns 74,381 shares of the company's stock, valued at approximately $10,277,222.77. This trade represents a 1.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 116,449 shares of company stock worth $15,463,316 over the last quarter. Insiders own 0.46% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，SVP Eric Shroff 在 3 月 3 日的交易中出售了 562 股該公司的股票。股票以 138.17 美元的平均價格出售，總交易額為 77,651.54 美元。交易後，這位高級副總裁現在直接持有 31,970 股公司的股票，價值約為 4,417,294.90 美元。這筆交易代表着他們持股比例減少了 1.73%。該出售在與 SEC 的法律文件中披露，可以通過此鏈接訪問。此外，EVP Andrea F. Wainer 在 3 月 3 日的交易中出售了 949 股雅培的股票。股票以 138.17 美元的平均價格出售，總價值為 131,123.33 美元。出售後，這位執行副總裁現在直接持有 74,381 股公司的股票，價值約為 10,277,222.77 美元。這筆交易代表着他們持股比例減少了 1.26%。該出售的披露可以在這裏找到。內部人士在上個季度出售了 116,449 股公司股票，價值 15,463,316 美元。內部人士持有公司股票的比例為 0.46%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A hedge fund recently raised its stake in Abbott Laboratories stock. Brighton Jones LLC raised its position in Abbott Laboratories (NYSE:ABT - Free Report) by 10.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 51,719 shares of the healthcare product maker's stock after buying an additional 4,755 shares during the period. Brighton Jones LLC's holdings in Abbott Laboratories were worth $5,850,000 at the end of the most recent reporting period. 75.18% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家對沖基金最近增加了對雅培股票的持股。根據該公司在最近向證券交易委員會提交的文件，Brighton Jones LLC 在第四季度將其在雅培（NYSE:ABT - 免費報告）的持股增加了 10.1%。該基金在此期間購買了額外的 4,755 股後，持有 51,719 股這家醫療產品製造商的股票。Brighton Jones LLC 在雅培的持股在最近的報告期末價值為 5,850,000 美元。75.18% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Abbott Laboratories</h2>
<div class="lb-trans"><h2>關於雅培</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p>
<div class="lb-trans"><p>雅培及其子公司在全球範圍內發現、開發、製造和銷售醫療保健產品。它分為四個部門：已建立的製藥產品、診斷產品、營養產品和醫療設備。該公司提供用於治療胰腺外分泌功能不足、腸易激綜合症或膽道痙攣、肝內膽汁淤積或抑鬱症狀、婦科疾病、激素替代療法、血脂異常、高血壓、甲狀腺功能減退、梅尼埃病和前庭眩暈、疼痛、發熱、炎症和偏頭痛的仿製藥，以及提供抗感染藥物克拉黴素、流感疫苗和調節結腸生理節律的產品。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>What Are Trending Stocks? Trending Stocks Explained</li>
<li>Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>XPO Buying $50 Million of Its Own Stock: Here's Why</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>Tesla Stock Eyes Breakout With Earnings on Deck</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，超過雅培</li>
<li>什麼是熱門股票？熱門股票解析</li>
<li>黃金反彈持續：這三隻礦業股票可能受益</li>
<li>特殊目的收購公司（SPAC）你需要知道的事項</li>
<li>XPO 購買 5000 萬美元的自家股票：原因在這裏</li>
<li>如何知道一隻股票是否支付股息以及何時支付</li>
<li>特斯拉股票在即將公佈財報時瞄準突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在雅培嗎？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮雅培之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而雅培並不在名單上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然雅培目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

雅培（NYSE:ABT）發佈 2025 年第二季度的收益指引